Aardvark Therapeutics, Inc. AARD
1.23 USD +0.03 (+2.50%)
At closeNov 3, 2026, 7:44 PM EST
1.20 -0.03 -2.43%
After hours · Nov 3, 7:44 PM ET
1.22 Day range 1.29
0.93 52-week range 16.60
- YTD
- -90.63%
- 1 year
- -88.16%
Financial health
Altman Z-Score
-1.90 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B3 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 4
Valuation
P/E -5.0×
FY 2022 5y median -18.9× FY 2025
P/S 0.0×
FY 2022 5y median 0.0× FY 2025
P/B 2.7×
FY 2022 5y median -7.2× FY 2025
P/FCF -5.3×
FY 2022 5y median -23.0× FY 2025
EV/EBITDA -4.2×
FY 2022 5y median -19.0× FY 2025
EV/Sales 0.0×
FY 2022 5y median 0.0× FY 2025
FCF Yield -18.9%
FY 2022 5y median -4.7% FY 2025
Profitability
Gross Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2022 5y median 0.0% FY 2025
ROE -54.0%
FY 2022 5y median 29.2% FY 2025
ROIC -58.6%
FY 2022 5y median -64.2% FY 2025
ROA -49.1%
FY 2022 5y median -58.8% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2022 FY 2025
Operating Income -175.3%
FY 2022 FY 2025
EPS (diluted) -177.9%
FY 2022 FY 2025
Free Cash Flow -198.2%
FY 2022 FY 2025
Financial Health
Current Ratio 10.6×
FY 2022 5y median 12.8× FY 2025
Quick Ratio 10.6×
FY 2022 5y median 12.8× FY 2025
Debt / Equity 0.0×
FY 2022 5y median -0.0× FY 2025
Net Debt / EBITDA 0.8×
FY 2022 5y median 1.4× FY 2025
Interest Coverage 0.0×
FY 2022 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2022 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2022 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31